Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 240

Sort by

Sort Order Select

Journal Articles

YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

Shuhong Hu, Yifei Liu, Xiang Zhang, Xiaoqi Wang, Yanting Li, Mengqian Chu, Jie Yin, Yanglan Fang, Changgeng Ruan, Li Zhu, Depei Wu, Yang Xu

Blood (2024) 144 (20): 2136–2148.

https://doi.org/10.1182/blood.2023023601

Published: 2024

Includes: Supplemental data

Journal Articles

Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects

Yuhua Ru, Jinjin Zhu, Huanle Gong, Mimi Xu, Ying Wang, Miao Miao, Suning Chen, Xiang Zhang, Yi Fan, Yang Xu, Jia Chen, Depei Wu

Blood (2024) 144 (Supplement 1): 3515.

https://doi.org/10.1182/blood-2024-202490

Published: 2024

Journal Articles

VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial

Wei Cui, Xiaoqian Chen, Qingya Cui, Zheng Li, Sifan Chen, Mengyun Li, Xuekai Li, Juan Chen, Yan Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3493.

https://doi.org/10.1182/blood-2024-207083

Published: 2024

Journal Articles

Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial

Yin Liu, Ye Zhao, Xiaofei Qi, Qiao Cheng, Jia Chen, Xiao Ma, Shengli Xue, Ying Wang, Xiaowen Tang, Huiying Qiu, Yang Xu, Depei Wu

Blood (2024) 144 (Supplement 1): 3535.

https://doi.org/10.1182/blood-2024-209696

Published: 2024

Journal Articles

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 851.

https://doi.org/10.1182/blood-2024-201380

Published: 2024

Journal Articles

Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Blood (2024) 144 (Supplement 1): 305.

https://doi.org/10.1182/blood-2024-194716

Published: 2024

Journal Articles

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Xiaoqian Chen, Wei Cui, Qingya Cui, Zheng Li, Sifan Chen, Mengyun Li, Xuekai Li, Juan Chen, Yan Yu, Xin Zhang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 270.

https://doi.org/10.1182/blood-2024-209163

Published: 2024

Journal Articles

Glofitamab Combined with Salvage Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Real-World Prospective Observational Study in Chinese Patients

Jingxian Gu, Tao You, Peng Xu, Jiebing Xiao, Wei Dai, Zhengming Jin, Xiao Ma, Depei Wu, Haiwen Huang

Blood (2024) 144 (Supplement 1): 6530.

https://doi.org/10.1182/blood-2024-203283

Published: 2024

Journal Articles

Construction and Validation of the New Prognostic Model Based on Genetic Risk Stratification for Chinese AML Patients

Fengli Li, Yangyang Ding, Shanglong Feng, Beibei Xie, Xunyi Jiao, Jinli Zhu, Qing Zhang, Qianshan Tao, Huiping Wang, Xin Liu, Depei Wu, Zhimin Zhai

Blood (2024) 144 (Supplement 1): 6164.

https://doi.org/10.1182/blood-2024-210615

Published: 2024

Journal Articles

Chemotherapy-Free Treatment with Venetoclax, Azacitidine and Flumatinib Induces an Early and Deep Molecular Response in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia：What Is the Underlying Mechanism?

Lingling Liu, Mengyun Li, Qingya Cui, Yangzi Li, Li Yao, Jianxin Fu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 5915.

https://doi.org/10.1182/blood-2024-206869

Published: 2024

Journal Articles

MRD Evaluation in a Transplant-Eligible NDMM Study

Yuhe Peng, Chengcheng Fu, Song Jin, Jingjing Shang, Weiqin Yao, Zhi Yan, Yingying Zhai, Li Yao, Hongmiao Shen, Xingyue Wu, Hongying You, Yue Huang, Jing Wang, Jiao Lu, Depei Wu

Blood (2024) 144 (Supplement 1): 6995.

https://doi.org/10.1182/blood-2024-207983

Published: 2024

Journal Articles

Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

Chengcheng Fu, Hongying You, Song Jin, Panfeng Wang, Lingzhi Yan, Liying Zhang, Tingting Lu, Xiao Gao, Lei Jiang, Hongchun Qiu, Jingjing Shang, Yingying Zhai, Weiqin Yao, Shuang Yan, Zhi Yan, Depei Wu

Blood (2024) 144 (Supplement 1): 6992.

https://doi.org/10.1182/blood-2024-210102

Published: 2024

Journal Articles

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Fu Cheng Cheng, Song Jin, Junling Zhuang, Xin Zhou, Fan Zhou, Yuhua Li, Kaiyang Ding, Ting Niu, Wenming Chen, Baijun Fang, Li-Li Chen, Rong Fu, Hao Zhang, Jiaping Fu, Xiuju Wang, Sha Liu, Lin Li, Depei Wu

Blood (2024) 144 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2024-204366

Published: 2024

Journal Articles

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Updated Results from a Phase II Study

Nana Ping, Changju Qu, Jiajie He, Hailing Liu, Rui Zou, Qian Zhu, Xiao Zhang, Depei Wu, Zhengming Jin

Blood (2024) 144 (Supplement 1): 6479.

https://doi.org/10.1182/blood-2024-198588

Published: 2024

Journal Articles

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

Si-Man Huang, Tong-Tong Zhang, Lan Dai, Chao-Ling Wan, Han-Yu Cao, Hai-Ping Dai, Ming-Zhu Xu, Depei Wu, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 5899.

https://doi.org/10.1182/blood-2024-204660

Published: 2024

Journal Articles

Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial

Mengyun Li, Qingya Cui, Xuekai Li, Wei Cui, Xiaoqian Chen, Yan Yu, Juan Chen, Xin Zhang, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 4197.

https://doi.org/10.1182/blood-2024-207017

Published: 2024

Journal Articles

Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial

Man Qiao, Suning Chen, Ying Wang, Shengli Xue, Xiaofei Yang, Depei Wu, Huiying Qiu, Yue Han, Yanming Zhang, Kourong Miao, Jihao Zhou, Xiaojin Wu, Miao Miao, Tao You, Xiao Ma, Haiping Dai

Blood (2024) 144 (Supplement 1): 4893.

https://doi.org/10.1182/blood-2024-207338

Published: 2024

Journal Articles

Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML

Kai-Wen Tan, Shanshan Pei, Miao Wang, Lan Dai, Hao Zhang, Chun-Yan Chen, Zhen-Qi Huang, Hai-Ping Dai, Ying Wang, Miao Miao, Yue Han, Xiaowen Tang, Huiying Qiu, Suning Chen, Aining Sun, Depei Wu, Zheng Li, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2024-204762

Published: 2024

Journal Articles

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Yue Zhou, Juan Chen, Qingya Cui, Haiping Dai, Zheng Li, Jia Yin, Wei Cui, Mengyun Li, Xuekai Li, Xin Zhang, Feiran Gong, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2024-199119

Published: 2024

Journal Articles

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2024-198959

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects

VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial

Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Glofitamab Combined with Salvage Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Real-World Prospective Observational Study in Chinese Patients

Construction and Validation of the New Prognostic Model Based on Genetic Risk Stratification for Chinese AML Patients

Chemotherapy-Free Treatment with Venetoclax, Azacitidine and Flumatinib Induces an Early and Deep Molecular Response in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia：What Is the Underlying Mechanism?

MRD Evaluation in a Transplant-Eligible NDMM Study

Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Updated Results from a Phase II Study

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial

Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial

Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only